JP2011501962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501962A5 JP2011501962A5 JP2010532219A JP2010532219A JP2011501962A5 JP 2011501962 A5 JP2011501962 A5 JP 2011501962A5 JP 2010532219 A JP2010532219 A JP 2010532219A JP 2010532219 A JP2010532219 A JP 2010532219A JP 2011501962 A5 JP2011501962 A5 JP 2011501962A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- nucleobase
- modified
- compound
- liver cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 201000007270 liver cancer Diseases 0.000 claims 6
- 210000002966 Serum Anatomy 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 229920000272 Oligonucleotide Polymers 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010063628 acarboxyprothrombin Proteins 0.000 claims 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000006011 modification reaction Methods 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 229960001904 EPIRUBICIN Drugs 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N p-dioxin Chemical group O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Claims (17)
- 肝臓癌の治療に用いるための、配列番号17、18、19、20、21、22、23、24、25、26、27、28、29、および30に記載の核酸塩基配列から選ばれる核酸塩基配列の少なくとも15連続核酸塩基を含む核酸塩基配列を有する15〜30結合ヌクレオシドからなる修飾オリゴヌクレオチド、を含む化合物。
- 修飾オリゴヌクレオチドからなる請求項1に記載の化合物。
- 該修飾オリゴヌクレオチドが、
(i)配列番号17、18、19、20、21、22、23、24、25、26、27、28、29、および30に記載の核酸塩基配列から選ばれる核酸塩基配列の少なくとも16、17、18、19、20、21、22、または23連続核酸塩基を含む核酸塩基配列、または
(ii)配列番号17、18、19、20、21、22、23、24、25、26、27、28、29、および30に記載の核酸塩基配列から選ばれる核酸塩基配列からなる核酸塩基配列
を有する請求項1または2に記載の化合物。 - 少なくとも1のヌクレオシド間結合が修飾ヌクレオシド間結合であるか、または各ヌクレオシド間結合が修飾ヌクレオシド間結合である請求項1〜3のいずれかに記載の化合物。
- 該修飾ヌクレオシド間結合がホスホロチオエートヌクレオシド間結合である請求項4に記載の化合物。
- 複数の各ヌクレオシドが糖修飾を含み、各ヌクレオシドが糖修飾を含む請求項1〜5のいずれかに記載の化合物。
- 各修飾糖が、独立して2'-O-メトキシエチル糖、2'-フルオロ糖、2'-O-メチル糖、または2環糖部分から選ばれる請求項6に記載の化合物。
- 少なくとも1のヌクレオシドが修飾核酸塩基を含む請求項1〜7のいずれかに記載の化合物。
- 該修飾核酸塩基が5-メチルシトシンである請求項8に記載の化合物。
- 少なくとも1のさらなる療法を投与することを含む方法により肝臓癌を治療するのに使用するための請求項1〜9のいずれかに記載の化合物。
- 少なくとも1のさらなる療法が化学療法剤である請求項10に記載の化合物。
- 化学療法剤が、5-フルオロウラシル、ゲムシタビン、ドキソルビシン、マイトマイシンc、ソラフェニブ、エトポシド、カルボプラチン、エピルビシン、イリノテカン、およびオキサリプラチンから選ばれる請求項11記載の化合物。
- 対象に対する該化合物の投与が、
i. 腫瘍サイズまたは腫瘍数の減少をもたらし、
ii. 転位の進行を抑制するかまたは遅くし、そして/または
iii. 対象の全体的生存時間または進行のない生存を延長する
請求項1〜12のいずれかに記載の化合物。 - 血清α-フェトプロテインが上昇するか、または血清des-γ-カルボキシプロトロンビンが上昇している対象の肝臓癌を治療するために用いるための請求項1〜13のいずれかに記載の化合物。
- 対象に対する該化合物の投与が、血清α-フェトプロテインまたは血清des-γ-カルボキシプロトロンビンを減少させる請求項1〜14のいずれかに記載の化合物。
- 肝臓癌がダイオキシン誘発肝臓癌である請求項1〜15のいずれかに記載の化合物。
- 肝臓癌が肝細胞癌である請求項1〜16のいずれかに記載の化合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98323107P | 2007-10-29 | 2007-10-29 | |
| US60/983,231 | 2007-10-29 | ||
| PCT/US2008/081645 WO2009058907A2 (en) | 2007-10-29 | 2008-10-29 | Targeting micrornas for the treatment of liver cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501962A JP2011501962A (ja) | 2011-01-20 |
| JP2011501962A5 true JP2011501962A5 (ja) | 2012-05-10 |
| JP5535076B2 JP5535076B2 (ja) | 2014-07-02 |
Family
ID=40524369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532219A Active JP5535076B2 (ja) | 2007-10-29 | 2008-10-29 | 肝臓癌を治療するための標的化ミクロｒｎａ |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US8211867B2 (ja) |
| EP (1) | EP2217248B1 (ja) |
| JP (1) | JP5535076B2 (ja) |
| CN (1) | CN101980712B (ja) |
| AU (1) | AU2008318778B2 (ja) |
| CA (1) | CA2704043C (ja) |
| IL (1) | IL205307A (ja) |
| WO (1) | WO2009058907A2 (ja) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2281888B1 (en) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| ES2461189T3 (es) | 2006-01-05 | 2014-05-19 | The Ohio State University Research Foundation | Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón |
| EP2369012A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
| US8507200B2 (en) | 2007-02-09 | 2013-08-13 | Northwestern University | Particles for detecting intracellular targets |
| ES2627059T3 (es) | 2007-08-03 | 2017-07-26 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
| WO2009058907A2 (en) | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
| CN102007223B (zh) * | 2008-02-28 | 2014-06-18 | 俄亥俄州立大学研究基金会 | 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物 |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| WO2011017456A2 (en) * | 2009-08-04 | 2011-02-10 | Northwestern University | Localized delivery of nanoparticles for therapeutic and diagnostic applications |
| EP2504452A4 (en) | 2009-11-23 | 2014-06-11 | Univ Ohio State Res Found | SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS |
| CA2781618A1 (en) * | 2009-11-25 | 2011-06-03 | Elitech Holding B.V. | Minor groove binder (mgb)-oligonucleotide mirna antagonists |
| WO2011076141A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Diagnostic kits comprising microrna biomarkers and methods for diagnosis of hepatocellular cancer |
| CN101831427B (zh) * | 2010-04-01 | 2012-07-18 | 清华大学深圳研究生院 | 一种预防肿瘤复发和抑制肿瘤生长的寡聚核酸及其应用 |
| EP2576785A4 (en) * | 2010-06-04 | 2014-12-24 | Univ Texas | REGULATION OF METABOLISM BY MIR-378 |
| JP5099570B2 (ja) * | 2010-07-12 | 2012-12-19 | 国立大学法人鳥取大学 | ｓｉＲＮＡ導入による新規ｈｉＰＳＣ作製法 |
| AU2011326032B2 (en) | 2010-11-12 | 2016-10-06 | The Ohio State University Research Foundation | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
| BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
| CN102140471B (zh) * | 2011-01-10 | 2013-11-20 | 清华大学深圳研究生院 | 一种抑制肿瘤生长的寡聚核酸及其应用 |
| CN102125696B (zh) * | 2011-01-11 | 2013-06-12 | 清华大学深圳研究生院 | 抑制肿瘤生长及血管生成的寡聚核酸组合物及其应用 |
| WO2012106591A1 (en) | 2011-02-03 | 2012-08-09 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-34 |
| CN103459598B (zh) | 2011-02-03 | 2016-08-10 | 米尔纳医疗股份有限公司 | Mir-124的合成模拟物 |
| US8420617B2 (en) | 2011-03-11 | 2013-04-16 | Biocell Laboratories | Multiantivirus compound, composition and method for treatment of virus diseases |
| CN102178959B (zh) * | 2011-03-15 | 2013-10-23 | 清华大学深圳研究生院 | 抑制肺转移肿瘤生长的siRNA及其寡聚核酸组合与应用 |
| WO2012145374A1 (en) * | 2011-04-19 | 2012-10-26 | Regulus Therapeutics Inc. | TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS |
| ES2868950T3 (es) * | 2011-04-25 | 2021-10-22 | Sanofi Sa | Compuestos de microARN y métodos para modular la actividad de miR-21 |
| US8697408B2 (en) * | 2011-05-06 | 2014-04-15 | New England Biolabs, Inc. | Ligation enhancement |
| WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| JP2014530612A (ja) | 2011-10-14 | 2014-11-20 | ジ・オハイオ・ステート・ユニバーシティ | 卵巣がんに関する方法および材料 |
| CN104619353A (zh) * | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
| JP2015511121A (ja) | 2012-01-20 | 2015-04-16 | ジ・オハイオ・ステート・ユニバーシティ | 浸潤性および予後に関する乳がんバイオマーカーシグネチャー |
| US8969317B2 (en) | 2012-04-25 | 2015-03-03 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
| JP2014027898A (ja) * | 2012-07-31 | 2014-02-13 | Yamaguchi Univ | 肝細胞がん発症リスクの判定方法 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| KR20180039162A (ko) * | 2015-08-20 | 2018-04-17 | 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 | 간 질환 및 병태를 치료하기 위한 방법 및 조성물 |
| WO2017184850A1 (en) * | 2016-04-20 | 2017-10-26 | Convida Wireless, Llc | Physical channels in new radio |
| WO2017184865A1 (en) | 2016-04-20 | 2017-10-26 | Convida Wireless, Llc | Configurable reference signals |
| CN111052625A (zh) | 2016-04-20 | 2020-04-21 | 康维达无线有限责任公司 | 下行链路同步 |
| US10390331B2 (en) | 2016-04-20 | 2019-08-20 | Convida Wireless, Llc | System information provisioning and light weight connection signaling |
| KR102454397B1 (ko) | 2016-05-11 | 2022-10-14 | 콘비다 와이어리스, 엘엘씨 | 새로운 라디오 다운링크 제어 채널 |
| CN109644089B (zh) | 2016-06-15 | 2022-04-26 | 康维达无线有限责任公司 | 用于新无线电的无许可上行链路传输 |
| WO2017218794A1 (en) | 2016-06-15 | 2017-12-21 | Convida Wireless, Llc | Upload control signaling for new radio |
| CN115835405A (zh) | 2016-06-15 | 2023-03-21 | 交互数字专利控股公司 | 用于无许可操作的方法及装置 |
| KR20240006080A (ko) | 2016-08-11 | 2024-01-12 | 인터디지탈 패튼 홀딩스, 인크 | 뉴 라디오를 위한 유연한 프레임 구조에서의 빔포밍 스위핑 및 트레이닝 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| AU2017353907B2 (en) | 2016-11-01 | 2023-11-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| WO2018097947A2 (en) | 2016-11-03 | 2018-05-31 | Convida Wireless, Llc | Reference signals and control channels in nr |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
| WO2020068251A1 (en) | 2018-09-27 | 2020-04-02 | Convida Wireless, Llc | Sub-band operations in unlicensed spectrums of new radio |
| CN109880907A (zh) * | 2019-03-26 | 2019-06-14 | 中国人民解放军第八一医院 | 一种肝癌细胞侵袭转移的分子机制研究方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003070884A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP4334165B2 (ja) | 2001-07-13 | 2009-09-30 | コニカミノルタホールディングス株式会社 | 静電潜像現像用トナーと画像形成方法及び画像形成装置 |
| CA2462144C (en) * | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| JP4369691B2 (ja) | 2003-06-26 | 2009-11-25 | 株式会社Ｉｄｘ | マイクロ波化学反応装置 |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| EP1654536A4 (en) * | 2003-08-07 | 2008-07-30 | Ocimum Biosolutions Inc | MODELING OF HEPATOCYTE PRIMARY TOXICITY IN THE RAT |
| JP3959722B2 (ja) | 2003-10-15 | 2007-08-15 | 住友金属工業株式会社 | 線材コイルの冷却装置 |
| EP2295604B1 (en) | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
| US20050182005A1 (en) * | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| EP2290071B1 (en) * | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| WO2006020768A2 (en) * | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| EP2281888B1 (en) | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| CN1800388A (zh) | 2005-01-07 | 2006-07-12 | 中国人民解放军军事医学科学院放射医学研究所 | 八种人源miRNA |
| WO2006111512A1 (en) * | 2005-04-19 | 2006-10-26 | Basf Plant Science Gmbh | Improved methods controlling gene expression |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| JP2007073737A (ja) | 2005-09-07 | 2007-03-22 | Toyo Ink Mfg Co Ltd | 複数の導電性回路層を有するプリント配線板並びにその製造方法 |
| DE102005046385B4 (de) | 2005-09-28 | 2012-03-22 | Siemens Ag | Verfahren und Vorrichtung zur Nachbearbeitung eines 3D-Bilddatensatzes, insbesondere für die virtuelle Kolonographie |
| JP4483757B2 (ja) | 2005-09-30 | 2010-06-16 | セイコーエプソン株式会社 | 有機ｅｌ装置及び光学装置 |
| JP2007097429A (ja) * | 2005-09-30 | 2007-04-19 | Mitsubishi Rayon Co Ltd | ｎｏｎ−ｃｏｄｉｎｇＲＮＡの検出データ補正方法 |
| US20070092882A1 (en) * | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| US20100286044A1 (en) * | 2005-12-29 | 2010-11-11 | Exiqon A/S | Detection of tissue origin of cancer |
| EP2388328A1 (en) * | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| US20080312099A1 (en) * | 2006-02-15 | 2008-12-18 | University Of Louisville Research Foundation, Inc. | Microarray, System, and Method for Detecting, Identifying, and Quantitating Micro-Rnas |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| CA3042781C (en) * | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| ES2425387T3 (es) * | 2006-07-13 | 2013-10-15 | The Ohio State University Research Foundation | Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre |
| US20080199961A1 (en) | 2006-08-25 | 2008-08-21 | Avi Biopharma, Inc. | ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS |
| AU2007314212B2 (en) | 2006-11-01 | 2014-05-29 | The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services | MicroRNA expression signature for predicting survival and metastases in Hepatocellular carcinoma |
| CA2671294A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| JP2009043353A (ja) | 2007-08-09 | 2009-02-26 | Pioneer Electronic Corp | タイトル付与装置、タイトル付与方法、タイトル付与プログラム、および記録媒体 |
| ES2463665T3 (es) * | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
| WO2009058907A2 (en) | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
-
2008
- 2008-10-29 WO PCT/US2008/081645 patent/WO2009058907A2/en active Application Filing
- 2008-10-29 AU AU2008318778A patent/AU2008318778B2/en active Active
- 2008-10-29 EP EP08844596.0A patent/EP2217248B1/en active Active
- 2008-10-29 JP JP2010532219A patent/JP5535076B2/ja active Active
- 2008-10-29 CN CN200880121316.9A patent/CN101980712B/zh active Active
- 2008-10-29 US US12/740,211 patent/US8211867B2/en active Active
- 2008-10-29 CA CA2704043A patent/CA2704043C/en active Active
-
2010
- 2010-04-25 IL IL205307A patent/IL205307A/en active IP Right Grant
-
2012
- 2012-05-25 US US13/481,105 patent/US8680067B2/en active Active
-
2014
- 2014-01-30 US US14/168,812 patent/US9150857B2/en active Active
-
2015
- 2015-08-24 US US14/833,889 patent/US9506062B2/en not_active Expired - Fee Related
-
2016
- 2016-10-26 US US15/334,422 patent/US9845470B2/en active Active
-
2017
- 2017-11-15 US US15/813,584 patent/US10301627B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501962A5 (ja) | ||
| JP2016501513A5 (ja) | ||
| JP2018528781A5 (ja) | ||
| JP2020115865A5 (ja) | ||
| JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
| IL264288A (en) | Methods and preparations for regulating expression of apolipoprotein(a) | |
| CN103080314B (zh) | 显性突变基因表达抑制剂 | |
| JP2017505623A5 (ja) | ||
| JP2015507625A5 (ja) | ||
| JP2015519891A5 (ja) | ||
| JP2011516410A5 (ja) | ||
| JP2012050438A5 (ja) | ||
| JP2010507579A5 (ja) | ||
| JP2016520312A5 (ja) | ||
| JP2014511686A5 (ja) | ||
| RU2016116849A (ru) | Композиции для модуляции экспрессии c90rf72 | |
| JP2015502365A5 (ja) | ||
| JP2020500929A5 (ja) | ||
| JP2008523157A5 (ja) | ||
| JP2014513954A5 (ja) | ||
| EP3364984B1 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| JP2014530004A5 (ja) | ||
| JP2011250796A5 (ja) | ||
| TWI762732B (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
| JP2014512186A5 (ja) |